Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 82, Issue 2, 2015, Pages 94-99

  Swierkot, Jerzy ^a   Bogunia Kubik, Katarzyna ^b   Nowak, Beata ^a,c   Bialowas, Katarzyna ^a   Korman, Lucyna ^a   Gebura, Katarzyna ^b   Kolossa, Katarzyna ^d   Jeka, Slawomir ^d   Wiland, Piotr ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF WROC AW   (Poland)

^d Clinical Department of Rheumatology and Connective Tissue Diseases Hospital University Number 2 Jana Biziela Bydgoszcz   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DNA; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1 ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1 BETA; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC CODE; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; REMISSION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETICS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84924341076     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.08.006     Document Type: Article

References (31)

1. Plant D., Prajapati R., Hyrich K.L., et al. Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate. Barton A: replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012, 64:665-670.
2. Criswell L.A., Lum R.F., Turner K.N., et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004, 50:2750-2756.
3. Fonseca J.E., Carvalho T., Cruz M., et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005, 64:793-794.
4. Seitz M., Wirthmuller U., Moller B., et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF{alpha}-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007, 46:93-96.
5. Bouma G., Crusius J.B., Oudkerk Pool M., et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996, 43:456-463.
6. Marotte H., Maslinski W., Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther 2005, 7:149-155.
7. Wijbrandts C.A., Dijkgraaf M.G., Kraan M.C., et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008, 67:1139-1144.
8. Mascheretti S., Hampe J., Kühbacher T., et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002, 2:127-136.
9. Kang C.P., Lee K.W., Yoo D.H., et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:547-552.
10. Marotte H., Pallot-Prades B., Grange L., et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006, 65:342-347.
11. Miceli-Richard C., Comets E., Verstuyft C., et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008, 67:478-484.
12. Lee Y.H., Rho Y.H., Choi S.J., et al. Association of TNF-alpha -308G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006, 27:157-161.
13. O'Rielly D.D., Roslin N.M., Beyene J., et al. TNFalpha- 308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 2009, 9:161-167.
14. Zeng Z., Duan Z., Zhang T., et al. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol 2013, 23:489-495.
15. Lee Y.H., Ji J.D., Bae S.C., et al. Associations between tumor necrosis factor-a (TNF-a) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-a blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2010, 37:740-746.
16. Pavy S., Toone E.J.M., Miceli-Richard C. Tumour necrosis factor a-308G? A polymorphism is not associated with response to TNF-a blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010, 69:1022-1028.
17. Tan R., Gibbons L., Potter C., et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010, 69:1029-1035.
18. Aggarwal B.B., Eessalu T.E., Hass P.E. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985, 318:665-667.
19. Valle Y., Ledezma-Lozano I.Y., Torres-Carrillo N., et al. Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis. Scand J Rheumatol 2009, 38:332-335.
20. Ongaro A., De Mattei M., Pellati A., et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?. Rheumatol Int 2008, 28:901-908.
21. Fabris M., Di P.E., D'Elia A., et al. Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002, 29:29-33.
22. Chatzikyriakidou A., Georgiou I., Voulgari P.V., et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology (Oxford) 2007, 46:1034-1035.
23. Toonen E.J., Coenen M.J., Kievit W., et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis 2008, 67:1174-1177.
24. Morales-Lara M.J., Cañete J.D., Torres-Moreno D., et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012, 79:591-596.
25. Matsukura H., Ikeda S., Yoshimura N., et al. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 2008, 27:765-770.
26. Pierik M., Vermeire S., Steen K.V., et al. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004, 20:303-310.
27. Hassan B., Maxwell J.R., Hyrich K.L., et al. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. Rheumatology (Oxford) 2010, 49:43-47.
28. de Paz B., Alperi-López M., Ballina-García F.J., et al. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J Rheumatol 2010, 37:503-511.
29. Potter C., Hyrich K.L., Tracey A., et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:69-74.
30. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011, 70:2063-2070.
31. Liu C., Batliwalla F., Li W., et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008, 14:575-581.